Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05176314 · ClinicalTrials.gov registry record · Phase 1
A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LY3527727) and Rosuvastatin in Healthy Participants
A Phase 1 study, sponsored by Loxo Oncology.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT05176314 is a Phase 1 study that has completed, run by Loxo Oncology. The registered enrollment target is 32 participants.
The verdict
NCT05176314, a Phase 1 study, has completed, sponsored by Loxo Oncology.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
The main purpose of this study is to determine the effect of pirtobrutinib on the levels of rosuvastatin in the blood stream in healthy participants. This study will also evaluate the safety and tolerability of rosuvastatin when administered in combination with pirtobrutinib in healthy participants. This study will last up to approximately 26 days excluding screening period.
Interventions
- DRUG Pirtobrutinib
- DRUG Rosuvastatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2022-01-11 |
| Est. Completion | 2022-04-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05176314
The ClinicalTrials.gov registry entry for NCT05176314 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Loxo Oncology, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pirtobrutinib is the first listed.
NCT05176314 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05176314 about?
NCT05176314 is a clinical study titled "A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LY3527727) and Rosuvastatin in Healthy Participants". The main purpose of this study is to determine the effect of pirtobrutinib on the levels of rosuvastatin in the blood stream in healthy participants. This study will also evaluate the safety and tolerability of rosuvastatin when administered in combination with pirtobrutinib in healthy participants....
What is the current status of trial NCT05176314?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2022-01-11. Estimated completion is 2022-04-20.
What interventions are being tested in trial NCT05176314?
The interventions under investigation include: Pirtobrutinib (DRUG), Rosuvastatin (DRUG).
Who is sponsoring clinical trial NCT05176314?
This trial is sponsored by Loxo Oncology, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.